{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:06:11Z","timestamp":1782831971701,"version":"3.54.5"},"reference-count":31,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>\n                    We aimed to compare efficacy of different patterns of antibiotics and explore the risk factors related to mortality in patients with bloodstream infections (BSIs) due to carbapenem-resistant\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    (CRKP). This study retrospectively included 89 patients with BSIs due to CRKP with complete data during the year of 2018 in the First Affiliated Hospital of Zhejiang University School of Medicine. Overall, the 28-day mortality was 47.2% (42\/89). Multivariate analysis of Cox regression revealed that hematological malignancy (hazard ratio [HR] 5.698; 95% confidence interval [CI], 2.405\u201313.504;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and Pitt bacteremia score (HR per unit increase, 1.303; 95% CI, 1.109\u20131.532;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.001) were identified as independent predictors for 28-day mortality. Among 70 patients with appropriate therapy, 35 received tigecycline (TGC)-based therapy, 20 received polymyxin B (PMB)-based therapy, 9 received ceftazidime\/avibactam-based therapy, and 6 patients had other kinds of antibiotics, including ciprofloxacin, amikacin, and cotrimoxazole. By adjusting variables selected by crude analysis, it showed that receiving PMB-based therapy provided a survival benefit comparing with TGC-based therapy (HR, 0.068; 95% CI, 0.018\u20130.260;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Hematological malignancy and Pitt bacteremia score were independent risk factors of death in patients with BSIs due to CRKP and PMB-based therapy improved survival rate compared with TGC-based therapy.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0455","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T11:44:35Z","timestamp":1593085475000},"page":"227-233","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Bloodstream Infections due to Carbapenem-Resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    : A Single-Center Retrospective Study on Risk Factors and Therapy Options"],"prefix":"10.1177","volume":"27","author":[{"given":"Lisha","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingquan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Child Health Care, Zhejiang University Children's Hospital, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yake","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Lab for Diagnostic and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02166-13"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv086"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03007-15"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03514.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S153246"},{"key":"e_1_3_3_8_2","first-page":"566","article-title":"The efficacy and safety of different antimicrobial regimens in carbapenem-resistant Klebsiella pneumoniae bloodstream infections [in Chinese]","volume":"58","author":"Sun W.M.","year":"2019","unstructured":"Sun W.M., , Zhou H., , Shen L., , Yang Q., , Ma W., , and Zhou J.Y.. 2019. The efficacy and safety of different antimicrobial regimens in carbapenem-resistant Klebsiella pneumoniae bloodstream infections [in Chinese]. Zhonghua Nei Ke Za Zhi, 58:566\u2013571.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.02.013"},{"key":"e_1_3_3_10_2","first-page":"1879","volume":"69","author":"Giamarellou H.","year":"2009","unstructured":"Giamarellou H., , and Poulakou G.. 2009. Multidrug-resistant gram-negative infections what are the treatment options? Drugs, 69:1879\u20131901.","journal-title":"Multidrug-resistant gram-negative infections what are the treatment options? Drugs"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80611-4"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.06.024"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000050454.01978.3B"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30228-1"},{"key":"e_1_3_3_16_2","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05879-11"},{"key":"e_1_3_3_18_2","article-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"The European Committee on Antimicrobial Susceptibility Testing","year":"2019","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, Available at: http:\/\/eucast.org (accessed November20, 2019).","journal-title":"Version"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2018.0339"},{"key":"e_1_3_3_20_2","first-page":"e01511","article-title":"Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia","volume":"63","author":"Wang X.","year":"2018","unstructured":"Wang X., , Wang Q., , Cao B., , Sun S., , Zhang Y., , Gu B., , Li B., , Liao K., , Zhao F., , Jin L., , Jin C., , Yang C., , Pei F., , Zhang Z., , and Wang H.. 2018. Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia. Antimicrob. Agents Chemother. 63:pii:e01511-18.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.05.012"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.231"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2233-5"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.014"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0090"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01882-17"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy660"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq431"},{"key":"e_1_3_3_30_2","first-page":"e02431","article-title":"Study Group","volume":"63","author":"Yin D.","unstructured":"Yin D., , Wu S., , Yang Y., , Shi Q., , Dong D., , Zhu D., , and Hu On behalf of the China Antimicrobial Surveillance Network F. (CHINET) Study Group. 2019. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63:e02431-18.","journal-title":"2019. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1213472"},{"key":"e_1_3_3_32_2","article-title":"Outcomes associated with carbapenem-resistant Enterobacteriaceae infection after solid organ transplantation in a multicenter study","author":"Huprikar S.","year":"2016","unstructured":"Huprikar S., , Casner L., , Pierrotti L.C, , Nellore A., , Madan R., , Garcia-Diaz J., , Jacobs S., , Lee D., , Trindade Clemente W., , Alangaden G., , La Hoz R., , Theodoropoulos N., , Miceli M., , Santoro-Lopes G., , Banach D., , Simon D., , and Patel G.. 2016. Outcomes associated with carbapenem-resistant Enterobacteriaceae infection after solid organ transplantation in a multicenter study. Abstract presented at the 16th American Transplant Congress, American Society of Transplant Surgeons and the American Society of Transplantation, Boston, June 11\u201315. Abstract no. 570.","journal-title":"Abstract presented at the 16th American Transplant Congress, American Society of Transplant Surgeons and the American Society of Transplantation"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:37:07Z","timestamp":1777667827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2019.0455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1089\/mdr.2019.0455"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0455","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}